{"id":3032,"date":"2017-01-18T01:24:31","date_gmt":"2017-01-18T06:24:31","guid":{"rendered":"http:\/\/allphasepharma.com\/dir\/?p=3032"},"modified":"2025-09-20T19:14:50","modified_gmt":"2025-09-21T01:14:50","slug":"indication-aom-making-come-back","status":"publish","type":"post","link":"https:\/\/allphasepharma.com\/dir\/2017\/01\/18\/3032\/indication-aom-making-come-back\/","title":{"rendered":"Is the AOM Indication Making a Come-Back?"},"content":{"rendered":"

\"\"<\/a><\/p>\n

We will get to the new Hoberman study[1]<\/a> in a moment, but first a bit of background. AOM, AECS and AECB were labeled indications for antibiotics in the 80s and 90s but were summarily thrown out from the indication catalogue shortly after the 1998 FDA Guidelines were published. The arguments for dismissal were many but can be condensed to these 2 issues: (1) many if not most patients with these conditions have a non-bacterial illness, and (2) the use of NI trials was not proper, as HESDE was never proven convincingly, at least not by FDA standards.<\/p>\n

In the absence of new Guidances to show us how to conduct a \u2018proper\u2019 otitis \/ sinusitis \/ bronchitis trial, sponsors have stayed away from these indications. They had experienced too much regulatory uncertainty of late with anti-infectives, did not think that superiority trials were feasible or had a reasonable chance of success. Big Pharma had \"\"<\/a>bigger fish to fry; therefore, they left the therapeutic area of anti-infectives without much regret and never looked back.<\/p>\n

The hope that one day we would have a diagnostic tool to differentiate viral from bacterial etiology is still just that \u2026a hope. Nevertheless, studies in recent years have punched a few holes into the FDA argument that these admittedly self-limiting diseases are trivial, all viral, and not influenced by antibiotics. They have shown that – even if mortality is zero and complication rates are low – there is a benefit for select patient groups in these indications along the \u201cfeel \/ function\u201d axis. Also there is a societal benefit in lost-days of work and use of health-care services that can also be established.<\/p>\n

In other words, the science is slowly catching up and refuting the FDA arguments.<\/p>\n

The recently published Hoberman trial was a well-designed trial in infants and toddlers\u00a0(age 6-23 months) comparing a 10-day treatment course of amoxiclav with a 5-day course. The trial was double-blind and placebo-controlled, the endpoint as robust as it gets: otoscopic improvement and complete symptomatic relief. Results consistently showed better efficacy for the 10-day treatment. The difference was highly significant statistically but importantly also showed meaningful symptomatic improvement.<\/p>\n

So, this is a landmark study of clinically relevance for managing AOM. It selected children not based on culture evidence of bacterial infection but on clinical entry criteria as clinicians would do in daily practice.<\/p>\n

<\/a>
Time to Treatment Failure. From T\u00e4htinen [2]<\/figcaption><\/figure>It is also a trial that demonstrated that treatment duration matters.

There are only few trials in the published literature that try to correlate efficacy with treatment duration, and they are in tonsillitis and in cystitis, which we will discuss in a future blog.<\/span><\/p>\n<\/div><\/p>\n

Note that the study did not have a \u2018pure\u2019 placebo control arm; in that case the treatment effect would have been even predictably more dramatic. However, a prior study by T\u00e4htinen, also double-blind and placebo-controlled, had such a placebo control arm and showed a very robust benefit with amoxiclav\u00a0[2]<\/a>. Btw, the funding for both studies came from NIH and the Foundation for Paediatric Research, not Big Pharma.<\/p>\n

Will these studies give sponsors enough confidence to test respiratory antibiotics as part of their PREA pediatric commitments? Will this study trigger a new FDA Guidance for ABOM allowing a NI design? Will the Agency wait for more evidence?<\/p>\n

The evidence is accumulating, albeit slowly.<\/p>\n

When the science moves on, FDA is likely to act eventually, but we never know exactly when the threshold will be reached for action. We also don\u2019t know FDA\u2019s HESDE requirements. However, we could argue that the Hoberman \/ T\u00e4htinen studies beat the quality of the 2 Snodgrass trials that FDA found sufficient as anchors for the ABSSSI indication.\u00a0We believe it is now time to amend prior rules which prohibited NI trials in AOM. It is sad though, if even the FDA had bigger fish to fry.<\/p>\n

Perhaps we should design and do Hoberman-like studies in tonsillitis, AECS and AECB before throwing the baby out with the bath water!<\/p>\n

Abbreviations:<\/strong>
\nAOM \u00a0 \u00a0 \u00a0 acute otitis media
\nABSSSI \u00a0 acute skin\/skin structure infection
\nAECS \u00a0 \u00a0 \u00a0acute exacerbation of chronic sinusitis (aka ABECS)
\nAECB \u00a0 \u00a0 \u00a0acute exacerbation of chronic\u00a0bronchitis\u00a0(aka ABECS)
\nPREA \u00a0 \u00a0 pediatric research equity act
\nHESDE \u00a0historical evidence of significant drug effect<\/p>\n

Publications:
\n<\/strong>[1]<\/a>\u00a0 A Hoberman. Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children. NEJM 2016;375:2446
\n[2]<\/a>\u00a0 P T\u00e4htinen. A placebo-controlled trial of antimicrobial treatment for acute otitis media. NEJM 2011;364:116<\/p>\n","protected":false},"excerpt":{"rendered":"

We will get to the new Hoberman study[1] in a moment, but first a bit of background. AOM, AECS and AECB were labeled indications for antibiotics in the 80s and 90s but were summarily thrown out from the indication catalogue shortly after the 1998 FDA Guidelines were published. The arguments Continue reading Is the AOM Indication Making a Come-Back?<\/span>→<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":3039,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":true,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[227,3,18],"tags":[1410,1625,81,1271,1883,1882,403,1881,519,5,1583,1855,1884,1880,745,153,1406,1879,1878,154,1885,1888],"class_list":["post-3032","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent_literature","category-the_news","category-the_viewpoint","tag-abecb","tag-abecs","tag-absssi","tag-allphase-pharma-consulting","tag-amoxicillin-clavulanate","tag-amoxiclav","tag-antibiotic-blog","tag-antibiotic-efficacy-in-aom","tag-aom","tag-fda","tag-harald-reinhart","tag-hesde","tag-hoberman","tag-new-labeling-indication","tag-ni","tag-non-inferiority","tag-otitis-media","tag-pediatric-study","tag-prea","tag-snodgrass","tag-tahtinen","tag-tonsillitis"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/AOM-slider.jpg?fit=640%2C180&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/p4KWFr-MU","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":3221,"url":"https:\/\/allphasepharma.com\/dir\/2017\/03\/14\/3221\/efficacy-treatment-duration-tipping-point\/","url_meta":{"origin":3032,"position":0},"title":"Efficacy and Treatment Duration: Where is the Tipping Point?","author":"Harald","date":"March 14, 2017","format":false,"excerpt":"Development pf antibacterials differs in several important ways from drug development in other areas, and the lack of standard dose-finding is just one of them. Dose-finding in its most basic form involves ascending amounts of drug for efficacy and safety; for antibiotics, however, an effective dose can be predicted nowadays\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/Tipping-Point-2.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/Tipping-Point-2.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/03\/Tipping-Point-2.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":839,"url":"https:\/\/allphasepharma.com\/dir\/2014\/09\/03\/839\/the-futile-quest-of-proofing-a-negative-in-the-presence-of-overwhelming-absence-of-harm\/","url_meta":{"origin":3032,"position":1},"title":"The Futile Quest of Proofing a Negative in the Presence of Overwhelming Absence of Harm","author":"Harald","date":"September 3, 2014","format":false,"excerpt":"The cartilage damage caused by fluoroquinolones in juvenile beagle dogs is not subtle:\u00a0 blister formation and erosions occur in a dose-dependent fashion resulting in reversible cartilage damage.\u00a0 These lesions can be seen not just histologically but even macroscopically.\u00a0 The animals are unable to walk as weight-bearing joints are predominantly affected.\u00a0\u2026","rel":"","context":"In "Recent Literature"","block_context":{"text":"Recent Literature","link":"https:\/\/allphasepharma.com\/dir\/category\/recent_literature\/"},"img":{"alt_text":"beagle dog","src":"http:\/\/allphasepharma.com\/dir\/wp-content\/uploads\/2014\/09\/beagle-dog.jpe","width":350,"height":200},"classes":[]},{"id":2064,"url":"https:\/\/allphasepharma.com\/dir\/2015\/10\/22\/2064\/polyphor-pol7080-and-the-journey-to-the-land-of-pyocyanea-part-3\/","url_meta":{"origin":3032,"position":2},"title":"Polyphor POL7080 And The Journey to The Land of Pyocyanea (Part 3)","author":"Harald","date":"October 22, 2015","format":false,"excerpt":"VABP is clearly the main\u00a0indication to be pursued by a drug like POL7080.\u00a0 Here is the question: How to conduct a study demonstrating efficacy for a drug which only has a\u00a0single-organism spectrum? \u00a0Which is actually no spectrum at all. \u00a0Existing guidelines for the development of ID drugs are indication-driven, with\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"bridge Pyocyanea-P3","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P3.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P3.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/10\/bridge-Pyocyanea-P3.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":2998,"url":"https:\/\/allphasepharma.com\/dir\/2017\/01\/12\/2998\/omissions-commissions-errors-blunders-solithromycin\/","url_meta":{"origin":3032,"position":3},"title":"Omissions \u2013 Commissions \u2013 Errors \u2013 Blunders – Solithromycin","author":"Harald","date":"January 12, 2017","format":false,"excerpt":"Cempra received a complete response letter (CRL) as a X-mas present from FDA, and the news was pretty bad for company investors. Bad, but not totally unexpected after the AMDAC meeting last November, which taught us a few new things about the drug. It also highlighted how strategic missteps can\u2026","rel":"","context":"In "QIDP Antibiotics"","block_context":{"text":"QIDP Antibiotics","link":"https:\/\/allphasepharma.com\/dir\/category\/qidp_antibiotic\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Solithro-Ketek-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Solithro-Ketek-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2017\/01\/Solithro-Ketek-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1887,"url":"https:\/\/allphasepharma.com\/dir\/2015\/08\/26\/1887\/avicaz-approval-and-labeling-restrictions\/","url_meta":{"origin":3032,"position":4},"title":"Avycaz Approval and Labeling Restrictions","author":"Harald","date":"August 26, 2015","format":false,"excerpt":"On Feb 25, 2015 the combination of ceftazidime\/avibactam (Avycaz) was approved by FDA for cUTI and cIAI infections in\u00a0patients \u2018who have limited or no alternative treatment options\u2019.\u00a0 As a QIDP drug, Avycaz\u00a0received priority review.\u00a0 Its label states that it is indicated for infections caused by pathogens proven or \u2018suspected to\u2026","rel":"","context":"In "Did you know...?"","block_context":{"text":"Did you know...?","link":"https:\/\/allphasepharma.com\/dir\/category\/interesting_facts\/"},"img":{"alt_text":"Avycaz - slider","src":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/Avycaz-slider.jpg?resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/Avycaz-slider.jpg?resize=350%2C200 1x, https:\/\/i0.wp.com\/allphasepharma.com\/dir\/wp-content\/uploads\/2015\/08\/Avycaz-slider.jpg?resize=525%2C300 1.5x"},"classes":[]},{"id":1362,"url":"https:\/\/allphasepharma.com\/dir\/2015\/04\/08\/1362\/arties-law-avoid-bad-advice-and-dont-follow-mission-impossible-advice\/","url_meta":{"origin":3032,"position":5},"title":"Artie\u2019s Law: Avoid Bad Advice and Don\u2019t Follow \u2018Mission Impossible\u2019 Advice","author":"Harald","date":"April 8, 2015","format":false,"excerpt":"In this day and age, few truly broad spectrum antibiotics are in development, although this does not hold true for narrow-spectrums.\u00a0 Just think of all the MRSA drugs (quinolones, FabI inhibitors), the pseudomonas drugs (NCEs and monoclonals) or some narrow spectrum drugs that will need to be tested in MDR\u2026","rel":"","context":"In "The Viewpoint"","block_context":{"text":"The Viewpoint","link":"https:\/\/allphasepharma.com\/dir\/category\/the_viewpoint\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/comments?post=3032"}],"version-history":[{"count":18,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3032\/revisions"}],"predecessor-version":[{"id":3069,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/posts\/3032\/revisions\/3069"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media\/3039"}],"wp:attachment":[{"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/media?parent=3032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/categories?post=3032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allphasepharma.com\/dir\/wp-json\/wp\/v2\/tags?post=3032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}